Val-chum, Limited Partnership

Adaerata, Limited Partnership

Caprion Biosciences Inc.

Marc Prentki

Murthy Madiraju

Erik Joly

Eustache Paramithiotis

Pascal Croteau

Rèmi Rabasa-Lhoret

Joel Lanoix

Sr Murthy Madiraju

Èrik Joly

Murthy S R Madiraju

The present invention provides biomarkers, methods and kits for diagnosing and prognosing the development of impaired glucose tolerance in a subject and the progression of diabetes in a subject, as well as methods for identifying a compound that can inhibit the development of impaired glucose tolerance and/or type 2 diabetes; reduce or slow down the progression of normal glucose tolerance to impaired fasting glycaemia, to impaired glucose tolerance, and/or to diabetes; and/or reduce or inhibit the development of complications associated with the disease in a subject, and methods for inhibiting the development of impaired glucose tolerance and/or type 2 diabetes; reducing or slowing down the progression of normal glucose tolerance to impaired fasting glycaemia, to impaired glucose tolerance, and/or to diabetes; and/or reducing or inhibiting the development of complications associated with the disease in a subject.

Type 2 diabetes biomarkers and uses thereof

The present disclosure relates to novel compounds, compositions containing same and methods for treating or preventing a condition associated with a deficient insulin secretion such as diabetes and metabolic syndrome in a subject in need thereof.

Insulin secretion promoting agents

Growing community of inventors

Mont-Royal, Canada

Marc Prentki